Connect with us

NEWS

Intellia’s One-Day CRISPR Shot Nears a First In-Body Approval

Intellia’s one-day CRISPR infusion cut HAE attacks 87% and now faces a March 10 FDA ruling that would test a lifetime of costly swelling drugs.

Published

on

Intellia Therapeutics is seeking FDA approval for lonvo-z, a one-day CRISPR infusion that cut hereditary angioedema attacks by 87% in Phase 3. The agency set a target action date of March 10, 2027.

If it says yes, lonvo-z would be the first CRISPR medicine edited inside the body rather than in a lab dish. That yes would also put a one-time liver edit up against a rare-disease market still built on daily pills and monthly shots, after a death in Intellia’s other in-body program forced a long safety pause.

What the Phase 3 HAELO Trial Found

HAELO enrolled 80 people with type 1 or type 2 hereditary angioedema, ages 16 and older, in nine months. Fifty-two got a single 50 mg intravenous dose of lonvoguran ziclumeran. Twenty-eight got placebo. The main look sat in weeks 5 to 28, after the edit had time to land in the liver.

Lonvo-z packages messenger RNA for CRISPR-Cas9 inside fatty particles, infuses them, and lets the liver take them up. The editor is aimed at KLKB1, the gene for prekallikrein, a liver protein that feeds kallikrein and bradykinin and helps blood vessels leak. The visit is billed as outpatient, one day, no chemo and no cells shipped to a factory.

THE HAELO SIX-MONTH SCORE

Endpoint (weeks 5 to 28) Lonvo-z (N=52) Placebo (N=28)
Mean monthly attacks 0.26 2.10
Attack-free and therapy-free 62% 11%
Monthly attacks needing on-demand treatment 0.19 1.79
Monthly moderate or severe attacks 0.11 1.23
AE-QoL change to week 28 -23.51 -6.47

A six-point drop on the Angioedema Quality of Life scale is the usual bar for a change a patient can feel. The lonvo-z arm cleared that bar with room. Every person on the active arm had fewer attacks than at baseline in the same window. All treatment-emergent events on lonvo-z were mild or moderate, and that arm recorded no serious adverse events through week 28. The events seen more often than on placebo were infusion reactions, headache, fatigue, back pain and upper respiratory infection.

John Leonard, M.D., Intellia’s president and chief executive, called the readout the first Phase 3 results “to deliver on the much-heralded promise of in vivo CRISPR gene editing.” Danny Cohn, M.D., Ph.D., an internist at Amsterdam University Medical Center and a HAELO principal investigator, said a one-time shot that could free people from attacks and from chronic medication would be “incredibly exciting” for a clinic that watches the disease’s unpredictability up close.

The New England Journal of Medicine published the HAELO manuscript in June 2026 (volume 395, pages 1471 to 1482). Intellia started a rolling biologics license application that April. On September 8, 2026, the FDA accepted the file, granted Priority Review, and told the company it is not currently planning an advisory committee.

The Yearly Drug Bill a Single Edit Would End

Hereditary angioedema causes sudden swelling in skin, gut and airway. A laryngeal attack can close the throat. Intellia still cites the old figure of one in 50,000 people. The US Hereditary Angioedema Association, working around the lack of a dedicated billing code, now puts nearly 10,000 people diagnosed with HAE in the United States, counting every type. Maria Natale, Intellia’s senior vice president of commercial, told investors on November 12, 2026, that about 7,500 people in the country are treated for type 1 or type 2 disease, the group HAELO actually studied.

Those patients already have a crowded shelf. Prevention means a daily pill, a shot every two to four weeks, or newer antibodies and RNA drugs dosed monthly or less. On-demand drugs still sit in bags and pockets because breakthrough attacks happen anyway. Kallikrein blockade is a proven idea. Lonvo-z’s bet is to do the blockade once, in DNA, and stop asking people to stay on the drugs.

THE FRANCHISES STILL PAID TO PREVENT SWELLING

  • Takeda’s Takhzyro: An injected plasma-kallikrein antibody that remaining competitors still treat as the standard shot.
  • BioCryst’s Orladeyo: A once-daily pill; the company guided 2026 net sales to $625 million to $645 million and bought Astria Therapeutics, in a deal valued at about $700 million, for a long-acting injectable still in late trials.
  • CSL’s Andembry: A monthly autoinjector approved June 16, 2025.
  • Ionis’s Dawnzera: An RNA drug given every four or eight weeks, approved August 21, 2025.
  • Ekterly from KalVista, now Chiesi: The first oral on-demand pill; Chiesi agreed in April 2026 to buy KalVista for about $1.9 billion.

That buying spree is the tell. Large rare-disease firms are still paying up for pills and shots that must be taken for life. A one-time KLKB1 knockout does not have to beat every drug on a six-month chart to hurt them. It has to last, get paid for once, and be easy enough that a clinic will offer it instead of another year of prophylaxis.

Intellia’s own claims work, presented at the American College of Allergy, Asthma and Immunology meeting, looked at 538 US patients on long-term prophylaxis for a median of 1.2 years and found almost 40% were non-adherent. Attack rates looked similar in the adherent and non-adherent groups. Breakthrough swelling is not only a problem for people who skip doses.

Casgevy Still Runs Through a Hospital Stay

The only CRISPR drug the FDA has cleared is Casgevy, from Vertex Pharmaceuticals and CRISPR Therapeutics, the first FDA-approved CRISPR/Cas9 therapy, authorized December 8, 2023, for sickle cell disease in people 12 and older with repeat pain crises, and later for transfusion-dependent beta thalassemia. Vertex set the list price at $2.2 million. On July 1, 2026, the agency extended the sickle cell and thalassemia labels down to age 2.

Casgevy is built one patient at a time. Blood stem cells come out, go to a plant, get edited at BCL11A so fetal hemoglobin returns, then go back in after busulfan chemotherapy wipes the marrow. The hospital stay runs about a month. Infertility is a known risk of the conditioning. In the sickle cell file, 44 people were treated and 29 of 31 with enough follow-up (93.5%) stayed free of severe vaso-occlusive crises for at least 12 months.

Lonvo-z skips that factory. There is no autologous lot, no search for a transplant bed, and no chemo. The trade is the one every in-vivo editor accepts: nobody pulls the edited cells back out to check for cuts at the wrong address, or in the wrong organ, before they go in. Immune reactions to the editor or the lipid coat are also on the list. Four years of quiet kallikrein in a few dozen people is the start of an answer, not the end of one.

A Death in Intellia’s Other Liver Trial

The same Cambridge company is running a second in-vivo CRISPR program, nexiguran ziclumeran, or nex-z, with Regeneron. That drug uses a 55 mg infusion to shut off TTR in the liver for transthyretin amyloidosis. It is not lonvo-z. It uses the same broad idea of sending Cas9 into hepatocytes, and it is the file that scared regulators.

THE HOLD THAT STILL SITS ON IN-VIVO EDITING

  1. September 30, 2025: A MAGNITUDE participant receives nex-z.
  2. October 29, 2025: The FDA pauses MAGNITUDE and MAGNITUDE-2 after Grade 4 liver transaminases and a rise in total bilirubin that met the protocol’s stopping rule.
  3. November 5, 2025: The participant, an older man with other illnesses, dies after being hospitalized.
  4. January 27, 2026: The agency lifts the hold on MAGNITUDE-2, the smaller polyneuropathy study of about 60 people.
  5. March 2, 2026: The agency removed the clinical hold on MAGNITUDE, the cardiomyopathy study of about 1,200 people.
  6. September 8, 2026: The FDA accepts the lonvo-z BLA with Priority Review.
  7. March 10, 2027: Lonvo-z PDUFA date.

Intellia later said the death followed sepsis after surgeons found a perforation and an ulcer in the abdomen, and the company does not tie that death to liver failure. The pause still happened because of the liver labs. To restart, Intellia agreed to closer liver-test monitoring, short-term steroids if enzymes rise early after dosing, and the exclusion of people with certain liver abnormalities. MAGNITUDE also now keeps out patients with recent cardiovascular instability and those whose ejection fraction is under 25% at screening.

HAELO, in a younger and otherwise different population, did not show that liver picture. Reviewers can still ask whether one lipid-Cas9 platform should be judged as a family. The louder objection around Intellia is not that HAELO missed its endpoints. It is that the first in-body CRISPR approval would arrive on a platform that already had to stop a sister trial after a fatal case.

Four Quiet Years After One Infusion

On November 12, 2026, Intellia put seven ACAAI presentations behind the durability claim. Across Phase 1/2 and HAELO, 93 patients received the proposed 50 mg commercial dose. The company said the overall attack-rate drop from baseline was 89% through up to four years of follow-up, that 97% never started long-term prophylaxis after the infusion, and that every one of the 93 was off prophylaxis at the last visit.

WHAT HELD AFTER THE INFUSION

  • Kallikrein: In Phase 1/2, mean plasma kallikrein fell 84% by week 4 and stayed there through four years.
  • Attacks after year one: Among 32 Phase 1/2 patients, the share who were attack-free after one year was at least 90% in each later month.
  • A six-month quiet stretch: The estimated chance of starting an attack-free and prophylaxis-free interval longer than six months rose from 81% at six months to 93% at 24 months.
  • Common events: Infusion-related reactions, headache, fatigue and nasopharyngitis each showed up in more than 15% of patients; Intellia said no new long-term risks have been identified.

Among 35 HAELO patients who had been on prophylaxis at entry and were randomized to lonvo-z, monthly attacks fell 81% against their own prior prophylaxis rate. Sixty-three percent had complete control after the edit, against a 20% figure for complete control as the best response those HAELO patients had reported on earlier prevention. That 81% is a before-and-after in people who already had access to today’s shots and pills. It is the number chronic-drug makers have to answer, not the 87% versus placebo.

Twenty-three Phase 1/2 patients sat for interviews a median of 2.4 years after dosing. All said their HAE was well controlled after lonvo-z, against 48% before it. Twenty-two of the 23, or 96%, called it an optimal therapy. Eighty-six percent said their definition of “well controlled” had changed, from managing symptoms and staying on drugs to having no attacks.

It’s very reassuring. That’s what you’re supposed to see.

Jonathan Bernstein, hereditary angioedema specialist, University of Cincinnati, investigator on a lonvo-z trial

Bernstein was talking about the four-year cut. Kallikrein that stays down is the point of a DNA edit. If it drifted back, the commercial story would collapse even with a perfect six-month p-value. It has not drifted in the people followed so far. The sample is still small, and HAELO’s placebo-controlled window was six months, not four years.

Step Therapy Is Already in the Launch Script

Intellia ended September 2026 with $614.8 million in cash and, on September 4, closed a term loan of up to $400 million with OrbiMed, $75 million of it funded up front. The company says that cash, plus the loan, funds operations at least into 2028, past a planned US launch. MAGNITUDE-2 finished enrollment in early November 2026. Nex-z remains the larger medical prize if ATTR-cardiomyopathy works. HAE is the file that can print a product first.

Natale said company research with more than 150 clinicians found 88% would prescribe a one-time treatment matching lonvo-z’s profile to at least one patient, and that 83% of more than 150 patients said they would ask their physician about it. She also said insurers are expected to demand step therapy, meaning some people would have to try a preventive drug before the infusion. Intellia has not named a price. It wants a launch in the first quarter of 2027, the first commercial patients in the second quarter after that launch, and a full ramp by month 12, through a network of authorized centers.

A one-day CRISPR visit that actually replaces years of $600,000-class prophylaxis would be paid like a gene therapy and used like a biologic. That is the second bill coming due on March 10, after the scientific one. Casgevy already showed that a CRISPR cure can sit on a label and still move slowly when the process is a transplant. Lonvo-z is the test of whether taking the factory out of the loop is enough, in a disease with a few thousand treated US patients and a shelf full of drugs that already work pretty well if people take them.

The FDA has said it does not currently plan an advisory committee. Leonard told investors on November 12, 2026, that an approval would make lonvo-z the first CRISPR medicine delivered inside the body. The 87% reduction in mean monthly attacks is already in the file. What is not in the file is a price, a step-therapy map, or four years of follow-up on all 93 patients. Those arrive after March 10, if they arrive at all.

Disclaimer: This article is news reporting and analysis of company trial data, FDA timelines and commercial plans. It is informational only and is not medical advice, a treatment recommendation, or investment advice. Lonvo-z remains an investigational therapy and is not FDA-approved; readers who have hereditary angioedema, or who are considering any gene-editing procedure, should talk with a qualified physician who treats the condition before changing care. Anyone weighing Intellia securities or other HAE-drug stocks should consult a licensed financial adviser. Figures, trial results, cash totals and regulatory dates reflect the company filings, trial presentations and agency notices cited above and may change as the review proceeds.

Harry is the editor of RTD JOURNAL, an independent publication that he owns, and ten years of journalism, first as a reporter, now as an editor, have left him with a habit of reading the documents other people skip. Annual reports are read to the footnotes, court filings to the exhibits, government releases to the methodology section, because that is where the numbers that matter usually sit. Each figure that reaches the page is checked against the document it came from, and claims that cannot be tied to a primary source are left out. That approach runs across the site's ten sections, written for an international readership: news, business and technology on one side, science, sports, entertainment, travel, lifestyle, gaming and auto on the other, all held to the same standard of evidence. A mistake, once found, is fixed on the article with a dated note that explains the change, as the site's public corrections policy requires. Readers can reach him with documents, questions or corrections at support@rtdjournal.com.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending